Top Fluoxetine Brands You Should Know About

Fluoxetine, a widely prescribed antidepressant, has gained popularity for its effectiveness in treating various mental health conditions. As mental health awareness grows, people seek trusted brands to ensure they receive quality medication. Numerous pharmaceutical companies have risen to the occasion, offering fluoxetine under various brand names while maintaining adherence to rigorous quality standards. Below, you can explore the best brands for fluoxetine, alongside insightful details about each one.

Illustration of fluoxetine

Best brands of fluoxetine in 2025

Prozac

Prozac, the brand name for fluoxetine, is a leading producer of this selective serotonin reuptake inhibitor (SSRI) antidepressant, widely prescribed for treating various mental health conditions such as depression, obsessive-compulsive disorder, and anxiety disorders. In 2022, the capsule form of fluoxetine, which includes Prozac, accounted for the highest market share of 52.50% and is expected to grow at the fastest CAGR during the forecast period. The market for fluoxetine, including Prozac, is projected to reach USD 1,367.46 million by 2031, growing at a CAGR of 3.8% from 2023 to 2031. North America, particularly the United States, is a significant market for Prozac due to the high prevalence of mental health conditions and a robust healthcare infrastructure. The increasing demand for fluoxetine is driven by the rising prevalence of mental health disorders, with 19.86% of adults in the United States experiencing a mental illness in 2022. For more details on Prozac, you can visit WebMD’s Prozac page.

Sarafem

Sarafem, a brand of fluoxetine hydrochloride, is a leading medication in the treatment of premenstrual dysphoric disorder (PMDD) and other conditions such as depression, obsessive-compulsive disorder, and bulimia nervosa. It is a selective serotonin reuptake inhibitor (SSRI) that has been shown to be effective, with studies indicating that the 20 mg dose can reduce symptoms by up to 36% compared to placebo. The drug is available in various strengths, including 10 mg, 15 mg, and 20 mg tablets, and is known for its efficacy in improving mood and physical symptoms. By 2020, depression was projected to become the second-largest disease globally, and fluoxetine, including Sarafem, is expected to hold a significant share in the global depression drug market, which is forecasted to cross USD 18 billion by 2024. Sarafem's effectiveness and widespread use make it a key player in the fluoxetine market.

Rapiflux

Rapiflux, a brand name for fluoxetine, is a highly regarded producer of this selective serotonin reuptake inhibitor (SSRI) antidepressant, which is used to treat various mental health conditions including depressive disorders, obsessive-compulsive disorder (OCD), and bulimia nervosa. In 2022, the capsule segment of fluoxetine, which includes Rapiflux, accounted for the highest market share of 52.50% and is expected to grow at the fastest CAGR during the forecast period of 2023-2031. Fluoxetine, the active ingredient in Rapiflux, has a bioavailability of 70% to 90% and is well absorbed, with peak plasma concentrations attained after 6 to 8 hours. The market size of fluoxetine is projected to reach USD 1,367.46 million by 2031, driven by the increasing prevalence of mental health disorders. Rapiflux is part of a competitive market with key players focusing on expanding their product offerings and market share. You can find more information about Rapiflux side effects.

Selfemra

Selfemra, a brand of fluoxetine, is a leading prescription medicine used for treating various mental health conditions, including depressive disorders, obsessive-compulsive disorder (OCD), bulimia nervosa, and panic disorders. In 2022, the fluoxetine market, which includes Selfemra, was valued at USD 980.47 million and is projected to reach USD 1,367.46 million by 2031, growing at a CAGR of 3.8%. North America, particularly the U.S., dominates the market with a significant share, driven by the high prevalence of mental health disorders and well-developed healthcare infrastructure. The capsule form of fluoxetine, such as Selfemra, accounted for the highest market share of 52.50% in 2022 and is expected to grow at the fastest CAGR due to its convenience and ease of use. The increasing demand for fluoxetine is also fueled by the rising prevalence of mental health issues, with 19.86% of adults in the U.S. experiencing a mental illness in 2022. For more information on potential side effects of Selfemra, visit their site.

Solaxin

Solaxin, a renowned brand in the pharmaceutical industry, stands out as a leading producer of fluoxetine, a selective serotonin reuptake inhibitor (SSRI) widely used for treating mental health conditions such as depression, obsessive-compulsive disorder, and bulimia nervosa. With a market share significant enough to contribute to the overall fluoxetine market size projected to reach USD 1,367.46 million by 2031, Solaxin's products are known for their efficacy and reliability. The brand's fluoxetine capsules, in particular, have seen high demand due to their convenience and ease of use, accounting for 52.50% of the market share in 2022. Solaxin's commitment to quality and innovation aligns with the growing need for mental health treatments, as evidenced by the rising prevalence of mental illnesses, with 19.86% of adults in the United States experiencing a mental illness in 2022. The brand's products are available in various forms, including capsules, tablets, and solutions, catering to diverse patient needs.

Fluoxetine by Teva Pharmaceuticals

Fluoxetine by Teva Pharmaceuticals is a leading brand in the global fluoxetine market, known for its high-quality selective serotonin reuptake inhibitor (SSRI) capsules used to treat depression, obsessive-compulsive disorder (OCD), and bulimia nervosa. The global fluoxetine market, driven by increasing mental health awareness and de-stigmatization, is projected to grow at a compound annual growth rate (CAGR) of 4.8% to reach $1.19 billion by 2028. Teva Pharmaceuticals, along with other key players like Sun Pharmaceutical and Aurobindo Pharma, dominates the market with a significant share. The medication is available in various forms, including 10 mg and 20 mg capsules, and its full effects are typically seen after several weeks of treatment. The market growth is also fueled by advances in diagnostic methods and the rise of telemedicine. For more details about their products, visit Teva Pharmaceuticals' Fluoxetine Capsules.

Fluoxetine by Sandoz

Fluoxetine by Sandoz is a leading medication in the treatment of major depressive disorder, obsessive-compulsive disorder, and bulimia nervosa, significantly decreasing binge-eating and purging activities. It is available in 10 mg and 20 mg capsules and has been shown to be effective in clinical trials. The global fluoxetine market, which includes Sandoz Fluoxetine, is projected to grow at a CAGR of 6.3% from 2024 to 2031, reaching a market size of USD 4.2 billion by 2031. Sandoz Fluoxetine is not indicated for patients under 18 years old due to potential behavioral and emotional changes. The drug's effectiveness and ongoing research in improving its adverse effects contribute to its steady market growth. For more detailed information about Sandoz Fluoxetine, please refer to their document.

Fluoxetine by Mylan

Fluoxetine, marketed by Mylan Pharmaceuticals Inc., is a widely prescribed selective serotonin reuptake inhibitor (SSRI) used in the treatment of major depressive disorder, anxiety, bulimia, and other mental health conditions. The Mylan 4350 pill, identified as Fluoxetine Hydrochloride 40 mg, is a blue and white, capsule/oblong shaped tablet. This medication is part of a market expected to grow at a CAGR of 5.2% from 2024 to 2033, reaching approximately USD 2.05 billion by 2033. Mylan's fluoxetine capsules are known for their cost-effectiveness and widespread availability, dominating the generic market segment. The drug is not a controlled substance under the Controlled Substances Act (CSA) and is available only by prescription. For more detailed information about Mylan 4350, you can visit Drugs.com.

Fluoxetine by Dr. Reddy’s Laboratories

Dr. Reddy's Laboratories is a prominent producer of Fluoxetine, known for its high-quality formulations. In FY03, the company reported revenues of Rs 1.9 billion from Fluoxetine capsules, although this was lower than the Rs 3.7 billion in FY02 due to one-time marketing exclusivity revenues in the previous year. Despite this, adjusting for Fluoxetine revenues, the overall revenue growth was 25% over FY02. The company's Fluoxetine capsules were a significant contributor to their North American revenues, with tizanidine tablets also playing a crucial role in sustaining market share. Dr. Reddy's Laboratories continues to be a key player in the global Fluoxetine market, driven by its robust R&D and strong market presence.

Fluoxetine by Aurobindo Pharma

Aurobindo Pharma is a leading producer of Fluoxetine, a selective serotonin reuptake inhibitor (SSRI) antidepressant, with final approval from the USFDA to manufacture and market Fluoxetine tablets in 10 mg and 20 mg strengths, which are generic versions of Eli Lilly's Prozac. The product is indicated for treating major depressive disorder, obsessive-compulsive disorder (OCD), and bulimia nervosa. As of 2020, the estimated market size for this product was USD 42 million for the 12 months ending February 2020. The fluoxetine market is projected to grow at a CAGR of 3.8% from 2023 to 2031, reaching USD 1,367.46 million by 2031. Aurobindo Pharma's robust product portfolio and global reach, exporting to over 150 countries, make it a significant player in the fluoxetine market.